Denali Therapeutics Inc. (DNLI) financial statements (2020 and earlier)

Company profile

Business Address 161 OYSTER POINT BLVD.
SOUTH SAN FRANCISCO, CA 94080
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments415464
Cash and cash equivalents7977
Short-term investments336387
Receivables 1
Prepaid expense 1
Other undisclosed current assets1514
Total current assets:430481
Noncurrent Assets
Operating lease, right-of-use asset34
Property, plant and equipment4725
Long-term investments and receivables40148
Long-term investments40148
Other noncurrent assets38
Total noncurrent assets:123181
TOTAL ASSETS:553662
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities320
Accounts payable32
Accrued liabilities 9
Employee-related liabilities 10
Deferred revenue19
Deferred rent credit 1
Contract with customer, liability11
Other liabilities240
Total current liabilities:4533
Noncurrent Liabilities
Long-term debt and lease obligation69 
Operating lease, liability69
Liabilities, other than long-term debt4482
Deferred revenue44
Contract with customer, liability57
Deferred rent credit 25
Other liabilities00
Total noncurrent liabilities:11382
Total liabilities:158115
Stockholders' equity
Stockholders' equity attributable to parent395547
Common stock11
Additional paid in capital819774
Accumulated other comprehensive income (loss)0(1)
Accumulated deficit(426)(228)
Total stockholders' equity:395547
TOTAL LIABILITIES AND EQUITY:553662

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
Gross profit:27129
Operating expenses(240)(176)
Operating loss:(213)(46)
Nonoperating income1510
Investment income, nonoperating53
Loss from continuing operations before income taxes:(198)(36)
Income tax benefit0 
Net loss available to common stockholders, diluted:(198)(36)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
Net loss:(198)(36)
Comprehensive loss:(198)(36)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent1(0)
Comprehensive loss, net of tax, attributable to parent:(197)(37)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: